Poor response to azithromycin in cutaneous leishmaniasis leading to a premature interruption of a multicentric phase iii clinical trial in Brazil

Revista da Sociedade Brasileira de Medicina Tropical

Volumn 47, Issue 6, 2014, Pages 756-762

  Toledo Junior, Antonio ^a   Daher, André Bastos ^b   Amaral, Thaís Alves ^b   Carvalho, Sílvio Fernando Guimarães ^c   Romero, Gustavo Adolfo Sierra ^d   Rabello, Ana ^b  

^a UNIVERSIDADE JOSÉ DO ROSÁRIO VELLANO   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c STATE UNIVERSITY OF MONTES CLAROS   (Brazil)

^d UNIVERSITY OF BRASILIA   (Brazil)

Author keywords

Azithromycin; Cutaneous leishmaniasis; Leishmania braziliensis; Meglumine antimoniate; Randomized controlled trial

Indexed keywords

AZITHROMYCIN; MEGLUMINE ANTIMONATE; ANTIINFECTIVE AGENT; ANTIPROTOZOAL AGENT; MEGLUMINE; MEGLUMINE ANTIMONIATE; ORGANOMETALLIC COMPOUND;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ARTHRALGIA; ARTICLE; BRAZIL; CLINICAL EVALUATION; CONFIDENCE INTERVAL; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; ECG ABNORMALITY; FEMALE; FOLLOW UP; HEALTH PRACTITIONER; HUMAN; IMMUNE DEFICIENCY; LABORATORY TEST; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MYALGIA; OPEN STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SKIN LEISHMANIASIS; CLINICAL TRIAL; CONTROLLED STUDY; EARLY TERMINATION OF CLINICAL TRIAL; LEISHMANIASIS, CUTANEOUS; MIDDLE AGED; ORAL DRUG ADMINISTRATION; TIME; TREATMENT FAILURE; YOUNG ADULT;

LEISHMANIA BRAZILIENSIS;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTIPROTOZOAL AGENTS; AZITHROMYCIN; BRAZIL; EARLY TERMINATION OF CLINICAL TRIALS; FEMALE; HUMANS; LEISHMANIASIS, CUTANEOUS; MALE; MEGLUMINE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; TIME FACTORS; TREATMENT FAILURE; YOUNG ADULT;

EID: 84921832665     PISSN: 00378682     EISSN: None     Source Type: Journal    
DOI: 10.1590/0037-8682-0266-2014     Document Type: Article

References (21)

1. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 2012; 7:e35671.
2. Ministério da Saúde. Sistema de Informação de Agravos de Notifi cação (Sinan Net). Reported cases of American Tegumentary Leishmaniasis [Internet]. Ministério da Saúde; 2013. [Cited 2014 May 13]. Available at: http://dtr2004.saude.gov.br/sinanweb/tabnet?dh?sinannet/lta/bases/ltabrnet.def/.
3. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet 2005; 366:1561-1577.
4. Toledo Jr AC, da Silva RE, Carmo RF, Amaral TA, Luz ZM, Rabello A. Assessment of the quality of life of patients with cutaneous leishmaniasis in Belo Horizonte, Brazil, 2009-2010. A pilot study. Trans R Soc Trop Med Hyg 2013; 107:335-336.
5. Machado PR, Penna G. Miltefosine and cutaneous leishmaniasis. Curr Opin Infect Dis 2012; 25:141-144.
6. Soto J, Soto P. Miltefosine: oral treatment of leishmaniasis. Expert Rev Anti Infect Ther 2006; 4:177-185.
7. Soto J, Toledo J, Gutierrez P, Nicholls RS, Padilla J, Engel J, et al. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis 2001; 33:E57-61.
8. Alrajhi AA, Ibrahim EA, De Vol EB, Khairat M, Faris RM, Maguire JH. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 2002; 346:891-895.
9. Sousa AQ, Frutuoso MS, Moraes EA, Pearson RD, Pompeu MM. High-dose oral fl uconazole therapy effective for cutaneous leishmaniasis due to Leishmania (Vianna) braziliensis. Clin Infect Dis 2011; 53:693-695.
10. Krolewiecki AJ, Romero HD, Cajal SP, Abraham D, Mimori T, Matsumoto T, et al. A randomized clinical trial comparing oral azithromycin and meglumine antimoniate for the treatment of American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis. Am J Trop Med Hyg 2007; 77:640-646.
11. Layegh P, Yazdanpanah MJ, Vosugh EM, Pezeshkpoor F, Shakeri MT, Moghiman T. Effi cacy of azithromycin versus systemic meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis. Am J Trop Med Hyg 2007; 77:99-101.
12. Momeni AZ, Shafi ei A, Emamjoeh M, Aminjavaheri M, Momeni A. Azithromycin is not effective in the treatment of old world cutaneous leishmaniasis. Eur J Dermatol 2006; 16:701-702.
13. Prata A, Silva-Vergara ML, Costa L, Rocha A, Krolewiecki A, Silva JC, et al. Effi cacy of azithromycin in the treatment of cutaneous leishmaniasis. Rev Soc Bras Med Trop 2003; 36:65-69.
14. Teixeira AC, Paes MG, Guerra JO, Prata A, Silva-Vergara ML. Low effi cacy of azithromycin to treat cutaneous leishmaniasis in Manaus, AM, Brazil. Rev Inst Med Trop Sao Paulo 2007; 49:235-238.
15. Teixeira AC, Paes MG, Guerra JO, Prata A, Silva-Vergara ML. Failure of both azithromycin and antimony to treat cutaneous leishmaniasis in Manaus, AM, Brazil. Rev Inst Med Trop Sao Paulo 2008; 50:157-160.
16. Oliveira-Silva F, Morais-Teixeira E, Rabello A. Antileishmanial activity of azithromycin against Leishmania (Leishmania) amazonensis, Leishmania (Viannia) braziliensis, and Leishmania (Leishmania) chagasi. Am J Trop Med Hyg 2008; 78:745-749.
17. Krolewiecki A, Leon S, Scott P, Abraham D. Activity of azithromycin against Leishmania major in vitro and in vivo. Am J Trop Med Hyg 2002; 67:273-277.
18. Tanyuksel M, Bas AL, Araz E, Aybay C. Determination of intracellular effi cacies of azithromycin against Leishmania major infection in human neutrophils in vitro. Cell Biochem Funct 2003; 21:93-96.
19. Passos VM, Fernandes O, Lacerda PA, Volpini AC, Gontijo CM, Degrave W, et al. Leishmania (Viannia) braziliensis is the predominant species infecting patients with American cutaneous leishmaniasis in the State of Minas Gerais, Southeast Brazil. Acta Trop 1999; 72:251-258.
20. Wordl Health Organization (WHO). Department of control of neglected tropical diseases. Sustaining the drive to overcome the global impact of neglected tropical diseases. Second WHO report on neglected tropical diseases. Geneve: WHO; 2013.
21. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev 2006; 19:111-126.